Valneva SE

VALN • Biotechnology

$6.89

▼ -0.17 (-2.41%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$592.85M

Crecimiento

6.5%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Liquidez saludable · 2.38Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 13 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:53 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$6.89

Change-2.41%

Shares Out86.04M

Market Cap$592.85M

52W Range4.75 - 12.25

Beta1.35

P/E-4.42

P/S18.36

P/B7.39

P/FCF-1,004.14

EV/Sales18.43

EV/EBITDA-21.78

Price$6.89

Change-2.41%

Shares Out86.04M

Market Cap$592.85M

52W Range4.75 - 12.25

Beta1.35

P/E-4.42

P/S18.36

P/B7.39

P/FCF-1,004.14

EV/Sales18.43

EV/EBITDA-21.78

EV/FCF-1,008.11

Earnings Yield-5.65%

FCF Yield-0.10%

Dividend Yield0.00%

Gross Margin38.66%

Oper. Margin-46.74%

Profit Margin-65.95%

Debt/Eq1.95

Current Ratio2.38

Quick Ratio1.85

Revenue 5Y6.49%

Target$11.00

Target Upside59.65%

Target Median$11.00

Target Range11.00 - 11.00

Volume29.29K

Avg Volume29.61K

EPS Surprise-0.21

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

58/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

64/100

Por qué este puntaje▼

Liquidez saludable · 2.38Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

VALN

Analyst sentiment

Based on 3 analyst votes · 2026-09-05

67/100

Neutral

Bullish

Hold

Bearish

Precio objetivo

2026-08-14

Bajo

$11.00

Promedio

$11.00

Mediana

$11.00

Alto

$11.00

Resumen de la compañía

IPO: 5/5/2021

Industria: Biotechnology

P/B i: 7.39

Deuda / Patrimonio i: 1.95

Margen operativo: -46.74%

Margen neto: -65.95%

ROE i: -

ROIC: -

Salud financiera

Puntaje12 / 20

Deuda / Patrimonio: 1.95

Ratio corriente: 2.38

Ratio rápido: 1.85

Estado: Good

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

Valneva SE

Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.

Fuente - Link

Competidores

ARVN ATXS AVBP DAWN DNA GERN IOVA MBX MGTX REPL

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Valneva: The Lyme Royalty Transition Changes The Earnings Model

Valneva (VALN) is transitioning from a low-margin vaccine manufacturer to a high-margin royalty and milestone model, anchored by its Lyme disease partnership with Pfizer. Recent financials were impacted by IXCHIQ-related charges, but restructuring is improving the expense base and cash runway, with about three years of funding at current burn rates. Pfizer's Lyme vaccine candidate, with 73% efficacy and EMA validation, positions VALN for significant royalty and milestone income if approved and successfully commercialized.

Seeking Alpha

European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application

Valneva SE (NASDAQ:VALN) stock is surging on Friday after the company and its partner Pfizer Inc. (NYSE:PFE) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, their Lyme disease vaccine candidate.

Benzinga

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application.

GlobeNewsWire

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR “Vaccine A.

Business Wire

Valneva SE (VALN) Q2 2026 Earnings Call Transcript

Seeking Alpha

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	-0.21	-0.42	-0.21
2026-03-16	-0.173	-0.68	-0.507
2025-11-20	-0.3	-0.61	-0.31
2025-08-12	-0.27	-0.16	0.11
2025-05-07	-0.31	-0.13	0.18
2025-03-20	-0.22	-0.54	-0.32
2024-11-07	-0.3	-0.15	0.15
2024-08-13	-0.39	-0.37	0.02
2024-05-07	0.77	0.89	0.12
2024-03-20	0.2	-0.5	-0.7
2023-11-09	-0.51	-0.54	-0.03
2023-09-21	-0.36	-0.26	0.1